R. Ferre

发表

Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein

D. Matthews, C. Janson, Ward W. Smith, 1994, Cell.

Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition.

K. Gajiwala, K. Ryan, A. Stewart, 2013, Structure.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

Bo Liu, Rose Ann Ferre, Tove Tuntland, 2002, Journal of medicinal chemistry.

Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants

K. Fennell, Wei Liu, O. Plotnikova, 2022, Journal of Biological Chemistry.

Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants

K. Fennell, O. Plotnikova, C. Steppan, 2022, bioRxiv.

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

K. Gajiwala, A. Kalgutkar, P. Verhoest, 2021, Science.

Structure-based design of novel human Pin1 inhibitors (II).

J. Thomson, S. Greasley, E. Kraynov, 2010, Bioorganic & medicinal chemistry letters.

Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation.

D. Matthews, T. Hendrickson, R. Ferre, 2000, Journal of medicinal chemistry.

Structure-based design of novel human Pin1 inhibitors (I).

Samantha Greasley, Liming Dong, D. Matthews, 2009, Bioorganic & medicinal chemistry letters.

Structure-based design of novel human Pin1 inhibitors (III): optimizing affinity beyond the phosphate recognition pocket.

Genevieve D Paderes, Samantha Greasley, Eugenia Kraynov, 2014, Bioorganic & medicinal chemistry letters.

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.

D. Matthews, T. Hendrickson, S. Webber, 1998, Journal of medicinal chemistry.

Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.

D. Matthews, T. Hendrickson, S. Webber, 1996, Journal of medicinal chemistry.

The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase

K. Gajiwala, N. Grodsky, Sergei L Timofeevski, 2017, The Journal of Biological Chemistry.

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.

X. Mu, J. Bienkowska, Zhou Zhu, 2021, Cancer cell.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.

D. Matthews, P. Rejto, P. W. Rose, 2003, Journal of medicinal chemistry.

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

D. Matthews, T. Hendrickson, S. Webber, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids.

D. Matthews, S. Webber, P. Dragovich, 1999, Bioorganic & medicinal chemistry letters.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.

D. Matthews, P. Rejto, T. Hendrickson, 1999, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.

D. Matthews, P. Dragovich, R. Ferre, 1999, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.

D. Matthews, R. Babine, S. Webber, 1998, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.

D. Matthews, R. Babine, S. Webber, 1998, Journal of medicinal chemistry.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.

Rose Ann Ferre, D. Matthews, P. Dragovich, 2002, Bioorganic & medicinal chemistry letters.

Design , Synthesis , and Evaluation of Nonpeptidic Inhibitors of Human Rhinovirus 3 C Protease

D. Matthews, T. Hendrickson, S. Webber, 2022 .

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Ping Chen, Simon Bergqvist, Xiu Yu, 2016, Molecular Cancer Therapeutics.

2.3 Å crystal structure of the catalytic domain of DNA polymerase β

Rose Ann Ferre, Z. Hostomska, Z. Hostomský, 1994, Cell.

Protein structure-based design, synthesis, and biological evaluation of 5-thia-2,6-diamino-4(3H)-oxopyrimidines: potent inhibitors of glycinamide ribonucleotide transformylase with potent cell growth inhibition.

C. Janson, C. Bartlett, M. Varney, 1997, Journal of medicinal chemistry.

Thioether benzenesulfonamide inhibitors of carbonic anhydrases II and IV: structure-based drug design, synthesis, and biological evaluation.

S. Greasley, E. Reyner, R. Ferre, 2010, Bioorganic & medicinal chemistry.

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

K. Gajiwala, J. Nieman, K. Ryan, 2020, Journal of medicinal chemistry.

Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.

D. Matthews, S. Webber, P. Dragovich, 2000, Bioorganic & medicinal chemistry letters.

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

Paolo Vicini, Deepak Dalvie, Chengyi Zhang, 2017, Journal of medicinal chemistry.

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.

J. Lapek, Sherry L. Niessen, M. McTigue, 2021, Journal of medicinal chemistry.

Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors.

K. Gajiwala, Sherry L. Niessen, B. Cravatt, 2017, Cell chemical biology.

Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).

S. Kazmirski, M. Hickey, G. Alton, 2011, Journal of medicinal chemistry.

Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery

Qiyue Hu, M. Catherine Johnson, Laura Lingardo, 2011, J. Comput. Aided Mol. Des..

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Deepak Dalvie, Michael Zientek, Rose Ann Ferre, 2016, Journal of medicinal chemistry.

Ack1: Activation and Regulation by Allostery

K. Gajiwala, R. Ferre, K. Maegley, 2013, PloS one.

The crystal structure of the RNA-dependent RNA polymerase from human rhinovirus: a dual function target for common cold antiviral therapy.

P. Dragovich, H. Parge, R. Ferre, 2004, Structure.

AG-024322 is a multi-targeted CDK inhibitor with potent antitumor activity in vivo

Gennady M Verkhivker, D. Knighton, C. Lewis, 2005 .

AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity

Gennady M Verkhivker, D. Knighton, C. Lewis, 2005 .

Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.

D. Matthews, B. Srinivasan, S. Webber, 2001, Bioorganic & medicinal chemistry letters.

Structural basis for Nirmatrelvir in vitro efficacy against the Omicron variant of SARS-CoV-2

W. Liu, K. Fennell, C. Steppan, 2022 .

Structure-Based Design of Novel PIN1 Inhibitors (I)

Samantha Greasley, D. A. Matthews, R. A. Ferre, 2009 .

K. Gajiwala, N. Sach, Sherry L. Niessen, 2016, Journal of medicinal chemistry.

Structure of pteridine reductase (PTR1) from Leishmania tarentolae.

M. Ouellette, D. Matthews, Ming Zhao, 2003, Acta crystallographica. Section D, Biological crystallography.